SAN FRANCISCO, CA – GigaGen reached a technical milestone in its partnership with Novartis which resulted in a $750K payment as well as selection for a highly competitive National Science Foundation (NSF) Phase IIb Grant that matches 50% of Novartis’ milestone.

NSF Phase IIb grants are rarely awarded and only based on the successful commercialization of innovative technology previously funded by a Phase II grant.

GigaGen has now raised over $5 million in aggregate grant funding to advance its internal therapeutics programs.  CEO Dr. Johnson is the Principal Investigator for the Phase IIb grants.